N/A N=185 Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing
Gastroesophageal Reflux Disease
Primary: Reflux Disease Questionnaire (RDQ) — -0.387; -0.296 score on a scale — p=0.78
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=59 Comparing the Performance of 1 Day Multifocal Contact Lenses
Presbyopia
Primary: Subjective At-home Ratings for Ease of Lens Handling for Insertion — 8.90; 8.28; 9.18 units on a scale
N/A N=35 Comparing The Performance Of Two Different Daily Disposable Lenses (MIKI)
Myopia
Primary: Overall Lens Fit Acceptance — 3.71; 3.73 units on a scale
Phase 2 N=194 A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate
Rheumatoid Arthritis
Primary: Treatment Phase: Percentage of Participants Who Achieved an American College of Rheumatology 20 (ACR20) Response at Week 12 Based on Non-responder Imputation (NRI)…
Phase 2 N=10 PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Chronic Phase Myelofibrosis · Primary Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis
Primary: European Leukemia Net -International Working Group (ELN-IWG) Criteria — 0 Participants
Phase 2 N=19 Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Metastatic Transitional Cell Carcinoma of the Urothelium
Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS
Phase 3 N=392 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
Dementia-related Psychosis
Primary: Time From Randomization to Relapse in the Double-blind (DB) Period — NA; NA days — p=0.0023
Phase 3 N=21 Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
Pulmonary Arterial Hypertension
Primary: Geometric Mean Ratio of Dose Normalized Area Under the Curve From Time Zero to Tau (AUCtau) for Bosentan Before and After Imatinib Administrations — 93.3; 109; 131…
Phase 3 N=399 Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Sotagliflozin 400 mg Versus Placebo) — -0.34; -1.03 percentage of HbA1c — p=<0.0001
Phase 2 N=35 Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Progression-Free Survival (PFS) Rate at 24 Weeks — 11.4 percentage of participants
Phase 2 N=116 Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise
Insulin · Exercise
Primary: Number of Participants With Manifestation of Any Symptom at Any Point During the Protocol — 4; 6; 6; 4 Participants
Phase 2 N=50 Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Primary: Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment) — 5.6; 5.5 months
N/A N=100 The SeriScaffold® Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery in Europe
Soft Tissue Support and Repair
Primary: Investigator Satisfaction With Seri® Surgical Scaffold on an 11-Point Scale — 8.8 Scores on a Scale
N/A N=431 Disrupt CAD III With the Shockwave Coronary IVL System
Coronary Artery Disease · Myocardial Infarction
Primary: Number of Participants Who Experienced Freedom From Major Adverse Cardiac Events (MACE) Within 30 Days Post-procedure — 92.2 percentage of participants
Phase 4 N=151 A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD
Alcohol Dependence · Posttraumatic Stress Disorder (PTSD)
Primary: Change in Percentage of Heavy Drinking Days Over the 12 Weeks of Study Treatment as Assessed by the Timeline Followback (TFLB) — -36.2; -25.1 percent heavy drinking days